The Principle and Derivation of Mrna Vaccine
DOI:
https://doi.org/10.54097/px931970Keywords:
vaccines, mRNA vaccines, mRNA applications, BNT162b2, cancer vaccine.Abstract
Research has focused on mRNA vaccine in recent years. The outbreak and spread of covid-19 have also spurred research on mRNA vaccines. The 2023 Nobel Prize in Physiology or Medicine went to Drew Weisman and Kariko Katalin in honor of their holding of US patents relating to the application of immunogenic-free nucleoside-modified RNA. When compared to conventional vaccinations, mRNA vaccines offer additional benefits, it is not only effective against infectious diseases, but also against some non-infectious diseases such as cancer. mRNA vaccines also have drawbacks, such as side effects from vaccination. This review will start with the characteristics of various traditional vaccines, and then introduce mRNA vaccines. ’Next, both the manufacture process and reactions after the administration of mRNA vaccine are discussed – Externally produced RNA is injected into the body, endocytosed by cells, and converted into immunostimulating proteins by ribosomes, then the body will identify and destroy the corresponding pathogen or cancer cells. By taking two diseases and corresponding mRNA vaccines as examples, the advantages and disadvantages of mRNA vacciniation are presented, like quick effect and side effects such as thrombosis, thrombocytopenia and so on. Finally, I will talk about the preparation methods of mRNA vaccines that are different from traditional vaccines.
Downloads
References
[1] https://en.wikipedia.org/wiki/Central_dogma_of_molecular_biology。
[2] https://historyofvaccines.org/vaccines-101/what-do-vaccines-do/different-types-vaccines。
[3] Chaudhary, N., Weissman, D. & Whitehead, K.A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov 20, 817–838 (2021).
[4] Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 2020 Oct 6;61(3): E304-E312. doi: 10.15167/2421-4248/jpmh2020.61.3.1530. PMID: 33150219; PMCID: PMC7595075.
[5] Echaide M, Chocarro de Erauso L, Bocanegra A, Blanco E, Kochan G, Escors D. mRNA Vaccines against SARS-CoV-2: Advantages and Caveats. Int J Mol Sci. 2023 Mar 21;24(6):5944. doi: 10.3390/ijms24065944. PMID: 36983017; PMCID: PMC10051235.
[6] Yasmin F, Najeeb H, Naeem U, et al. Adverse events following COVID‐19 mRNA vaccines: a systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immun Inflamm Dis. 2023;11: e807. 10.1002/iid3.807
[7] Wang B, Pei J, Xu S, Liu J, Yu J. Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities. Front Immunol. 2023 Sep 6; 14:1246682. doi: 10.3389/fimmu.2023.1246682. PMID: 37744371; PMCID: PMC10511650.
[8] Kaczmarek M, Poznańska J, Fechner F, Michalska N, Paszkowska S, Napierała A, Mackiewicz A. Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review. Cells. 2023 Aug 28;12(17):2159. doi: 10.3390/cells12172159. PMID: 37681891; PMCID: PMC10486481.
[9] Sara Sousa Rosa, Duarte M.F. Prazeres, Ana M. Azevedo, Marco P.C. Marques, mRNA vaccines manufacturing: Challenges and bottlenecks, Vaccine, Volume 39, Issue 16, 2021
[10] Whitley J, Zwolinski C, Denis C, Maughan M, Hayles L, Clarke D, Snare M, Liao H, Chiou S, Marmura T, Zoeller H, Hudson B, Peart J, Johnson M, Karlsson A, Wang Y, Nagle C, Harris C, Tonkin D, Fraser S, Capiz L, Zeno CL, Meli Y, Martik D, Ozaki DA, Caparoni A, Dickens JE, Weissman D, Saunders KO, Haynes BF, Sempowski GD, Denny TN, Johnson MR. Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials. Transl Res. 2022 Apr; 242:38-55. doi: 10.1016/j.trsl.2021.11.009. Epub 2021 Dec 4. PMID: 34871810; PMCID: PMC8641981.
[11] Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, Khan W. A Comprehensive Review of mRNA Vaccines. Int J Mol Sci. 2023 Jan 31;24(3):2700. doi: 10.3390/ijms24032700. PMID: 36769023; PMCID: PMC9917162.
[12] Bloom, K., van den Berg, F. & Arbuthnot, P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther 28, 117–129 (2021). https://doi.org/10.1038/s41434-020-00204-y
[13] Kim SC, Sekhon SS, Shin WR, Ahn G, Cho BK, Ahn JY, Kim YH. Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Mol Cell Toxicol. 2022;18(1):1-8. doi: 10.1007/s13273-021-00171-4. Epub 2021 Sep 20. PMID: 34567201; PMCID: PMC8450916.
[14] Ramachandran S, Satapathy SR, Dutta T. Delivery Strategies for mRNA Vaccines. Pharmaceut Med. 2022 Feb;36(1):11-20. doi: 10.1007/s40290-021-00417-5. Epub 2022 Jan 30. PMID: 35094366; PMCID: PMC8801198.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







